Background This study used data from different sources to identify the extent of the unmet
| INTRODUCTION
In patients with type 2 diabetes mellitus (T2DM), early intervention to achieve and maintain glycemic control is essential to reduce the risk of diabetes-related vascular disease and associated long-term complications.
1,2 Current treatment guidelines recommend that patients achieve and maintain their glycated hemoglobin (HbA 1c ) level below a certain target, often 7%, with the option to increase or decrease this threshold depending on the clinical and demographic characteristics of the individual patient, such as age and gender. [3] [4] [5] Moreover, the exact target can vary between different countries/regions, and the target may change for an individual patient during the course of their disease. 6 A patient's HbA 1c level is a reflection of the sum of blood glucose exposure from the combination of fasting plasma glucose (FPG; when hepatic glucose production predominates) and postprandial plasma glucose (PPG; primarily due to dietary glucose). Both PPG and FPG need to be addressed to achieve sustained glycemic control. 4, 7 However, the relative contribution of FPG and PPG to HbA 1c can vary considerably depending on factors such as lifestyle, duration of disease, current treatment class, 8, 9 and race and ethnicity. approximately 60% of patients to achieve HbA 1c ≤7% with insulin glargine or NPH, although the proportion of patients who achieved this target without hypoglycemia was higher with insulin glargine.
11
For patients who are not successful in achieving target HbA 1c with basal insulin despite meeting FPG targets, additional treatment may be required to address residual hyperglycemia associated with PPG excursions. 12 A pooled analysis of six similarly designed randomized controlled trials (RCTs) of insulin glargine initiation showed that for patients with HbA 1c >7% despite OGLT therapy, basal hyperglycemia dominated glucose exposure; however, after 24 to 28 weeks of basal insulin therapy, postprandial hyperglycemia became predominant. 9 In general, the contribution of FPG to HbA 1c is greater at higher HbA 1c levels, with the contribution of PPG being more consistent across a range of HbA 1c values. 10, 13, 14 The potential benefits, with respect to glycemic control, of adding an agent that targets PPG excursions to basal insulin have been demonstrated in several recent studies of dipeptidyl peptidase-4 inhibitors and some GLP-1 receptor agonists. [15] [16] [17] The identification of patients failing to achieve HbA 1c targets with basal insulin is important to ensure that treatment can be adjusted promptly. Moreover, monitoring FPG in patients failing to meet target HbA 1c can be used to differentiate between individuals who will benefit from further basal insulin titration and patients who require addition of a prandial therapy to address PPG.
The aim of this retrospective analysis was to highlight the global extent of the problem of residual hyperglycemia among patients with T2DM after the initiation of basal insulin, including patients who have failed to achieve glycemic control previously with OGLTs. The analysis uses evidence from RCTs and real-world data to identify the patients who would most benefit from treatment intensification with a prandial agent. Potential predictive factors that could be used to identify these patients were also evaluated.
| MATERIALS AND METHODS
This study set out to evaluate glycemic control, as determined by 
| Data sources
To gain a broad-based view, patient data were obtained from three distinct sources: RCTs, observational clinical trial registries (CTRs), and electronic medical record (EMR) databases.
RCTs were identified by a systematic search of the US National The literature search based on the aforementioned search string identified a total of 110 publications, of which 63 were excluded on the basis that they were not randomized interventional clinical trials or did not report data. Of the remaining 47 publications, additional exclusions were seven reports of post hoc analyses, 28 studies with a duration longer or shorter than the range mentioned previously, and five reports of studies where access to patient-level data was not available. Therefore, a total of seven RCTs published between 2003
and 2010 met the criteria and were included in the analysis [21] [22] [23] [24] [25] [26] [27] ( Table 1 ). The comparator to insulin glargine was NPH insulin in five studies, insulin detemir in one study, and premixed 70% human NPH/ 30% regular insulin (70/30) in one study; the continuation of existing OGLTs was permitted in some studies; only patients receiving basal insulin, including insulin glargine, NPH insulin, and insulin detemir, were included in these post hoc analyses; patients receiving premixed insulin were excluded because of the rapid-acting insulin component. 
| Statistical analysis

| Residual hyperglycemia in CTRs
The glycemic status of patients in the ALOHA, CREDIT, and FINE-Asia studies who were included in this analysis is summarized in Figure 3 .
The proportion of patients with residual hyperglycemia ranged from 31.5% in the CREDIT study at 4 years to 35.6% in the ALOHA study after 6 months of treatment. Across the CTRs, 21.8% to 33.6% of patients were well controlled, with the highest proportion in the 
| Residual hyperglycemia in EMR databases
The glycemic status of eligible patients in the three EMR databases at 1-year follow-up on basal insulin therapy is summarized in Figure 4 .
The proportion of patients with residual hyperglycemia was 25.4%
for German patients, 23.9% for US patients, and 31.8% for UK patients. The proportion of well-controlled patients was low across all three databases, being highest in Germany at 21.0% and lowest in the United Kingdom at 4.4%. Conversely, uncontrolled hyperglycemia was more common, with the highest rates reported in the United Kingdom and the US (63.8% for both) and the lowest rates in Germany (53.6%).
No consistent global predictors of residual hyperglycemia could be identified reliably, although there was a trend toward significance for baseline HbA 1c levels in some countries.
| DISCUSSION
Data from this analysis reveal a high prevalence of patients on basal insulin with residual hyperglycemia, as defined by failure to achieve However, pragmatically, patients with high baseline HbA 1c would need to achieve an improvement that was both proportionally and absolutely greater to achieve glycemic targets, and this could explain the results seen in this analysis.
Previous studies of patients with T2DM have identified a link between female sex and poor glycemic control. [34] [35] [36] However, it should be noted that other studies have identified little or no difference between male and female patients with T2DM with respect to glycemic outcomes. 37 Sensitivity analyses indicate that a significant proportion there are also differences in national and regional guidelines to consider. Thus, using a cutoff value based on the regional guidelines at the time the studies were conducted may better reflect the real-world unmet need for each region.
Owing to a need for access to patient-level data, only RCTs conducted by the study sponsor were included in the analysis. A consequence of this is that all RCTs that met the specified inclusion criteria had insulin glargine as the comparator. Patients receiving other basal insulins were included in the analysis (NPH insulin in five studies and insulin detemir in one study) but only where the comparator was insulin glargine.
No attempt was made to account for previous background therapies or concomitant medication, including OGLTs, in this analysis.
However, the continuation of existing OGLTs when receiving basal insulin is an established treatment paradigm in T2DM, 5 and many patients treated with basal insulin will continue to receive background OGLT therapies during clinical trials. Patients who are initiating basal insulin treatment-the population of interest in our analysis-have T2DM that has progressed beyond the point where it can be controlled effectively with OGLTs. Therefore, it is common practice not to stratify clinical trial results according to patients' background OGLT medication. In the present analysis, which included real-world data, the emphasis was on the unmet medical needs of a diverse group of patients, who were all receiving basal insulin therapy. Thus, from the perspective of clinicians and payers, the current analysis was designed appropriately to illustrate the generalized unmet medical need in the basal insulin-treated patient population, without additionally controlling for background therapies.
It is important to remember that hyperglycemia is driven by a combination of basal hyperglycemia and postprandial hyperglycemia, and the difference between the two may be important when selecting agents for treatment intensification. 49, 50 In this study, a single FPG value was used to identify patients who failed to achieve 
